However, IL-8 can also increase the expression of inhibitory immune checkpoints such as PD-L1 in immune cells and cancer cells (Wu et al., 2019; Fousek et al., 2021), thus allowing the use of PD-1/PD-L1–blocking antibodies to achieve stronger antitumor effects. Here, CXCL8 is linked to cancer.